[Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)].
Identifieur interne : 003671 ( Ncbi/Merge ); précédent : 003670; suivant : 003672[Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)].
Auteurs : Y. Shi [République populaire de Chine] ; N. Wang [République populaire de Chine] ; Q M Zou [République populaire de Chine]Source :
- Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] [ 0253-9624 ] ; 2020.
Abstract
The outbreak of 2019 novel coronavirus (2019-nCoV) infection poses a serious threat to global public health. Vaccination is an effective way to prevent the epidemic of the virus. 2019-nCoV along with severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) belong to the same β-genus of coronavirus family. Base on the previous experience and the technical platform of developing SARS-CoV and MERS-CoV vaccines, scientists from all over the world are working hard and quickly on the related fields. There are substantial progress in these fields including the characterizing the 2019-nCoV virus, identification of candidate antigens and epitopes, establishment of animal models, characterizing the immune responses, and the design of vaccines. The development of 2019-nCoV vaccines cover all types: inactivated virus vaccine, recombinant protein vaccine, viral vector-based vaccine, mRNA vaccine, and DNA vaccine, et al. As of March 2020, two 2019-nCoV vaccines have entered phase I clinical trials. One is named as Ad5-nCoV developed by the Chinese Institute of Biotechnology of the Academy of Military Medical Sciences and Tianjin Cansino Biotechnology Inc. Ad5-nCoV is based on the replication-defective adenovirus type 5 as the vector to express 2019-nCoV spike protein. The another vaccine is mRNA-1273 developed by the National Institute of Allergy and Infectious Diseases and Moderna, Inc.. RNA-1273 is an mRNA vaccine expressing 2019-nCoV spike protein. Although the rapid development of 2019-nCoV vaccine, it still faces many challenges with unknown knowledge, including the antigenic characteristics of the 2019-nCoV, the influence of antigenic variation, the protective immune response of host, the protection of the elderly population, and the downstream manufacturing process of the new vaccine. The safety and efficacy of vaccines are the first priority for vaccine development and should be carefully evaluated.
DOI: 10.3760/cma.j.cn112150-20200317-00366
PubMed: 32234130
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000420
- to stream PubMed, to step Curation: 000420
- to stream PubMed, to step Checkpoint: 000018
Links to Exploration step
pubmed:32234130Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)].</title><author><name sortKey="Shi, Y" sort="Shi, Y" uniqKey="Shi Y" first="Y" last="Shi">Y. Shi</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Biopharmaceutical Research, West China Hospital, Sichuan University, Chengdu 610041, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Biopharmaceutical Research, West China Hospital, Sichuan University, Chengdu 610041</wicri:regionArea><wicri:noRegion>Chengdu 610041</wicri:noRegion></affiliation></author><author><name sortKey="Wang, N" sort="Wang, N" uniqKey="Wang N" first="N" last="Wang">N. Wang</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Biopharmaceutical Research, West China Hospital, Sichuan University, Chengdu 610041, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Biopharmaceutical Research, West China Hospital, Sichuan University, Chengdu 610041</wicri:regionArea><wicri:noRegion>Chengdu 610041</wicri:noRegion></affiliation></author><author><name sortKey="Zou, Q M" sort="Zou, Q M" uniqKey="Zou Q" first="Q M" last="Zou">Q M Zou</name><affiliation wicri:level="1"><nlm:affiliation>National Engineering Research Center of Immunological Products, Army Medical University, Chongqing 400038, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>National Engineering Research Center of Immunological Products, Army Medical University, Chongqing 400038</wicri:regionArea><wicri:noRegion>Chongqing 400038</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32234130</idno><idno type="pmid">32234130</idno><idno type="doi">10.3760/cma.j.cn112150-20200317-00366</idno><idno type="wicri:Area/PubMed/Corpus">000420</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000420</idno><idno type="wicri:Area/PubMed/Curation">000420</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000420</idno><idno type="wicri:Area/PubMed/Checkpoint">000018</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000018</idno><idno type="wicri:Area/Ncbi/Merge">003671</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)].</title><author><name sortKey="Shi, Y" sort="Shi, Y" uniqKey="Shi Y" first="Y" last="Shi">Y. Shi</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Biopharmaceutical Research, West China Hospital, Sichuan University, Chengdu 610041, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Biopharmaceutical Research, West China Hospital, Sichuan University, Chengdu 610041</wicri:regionArea><wicri:noRegion>Chengdu 610041</wicri:noRegion></affiliation></author><author><name sortKey="Wang, N" sort="Wang, N" uniqKey="Wang N" first="N" last="Wang">N. Wang</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Biopharmaceutical Research, West China Hospital, Sichuan University, Chengdu 610041, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Biopharmaceutical Research, West China Hospital, Sichuan University, Chengdu 610041</wicri:regionArea><wicri:noRegion>Chengdu 610041</wicri:noRegion></affiliation></author><author><name sortKey="Zou, Q M" sort="Zou, Q M" uniqKey="Zou Q" first="Q M" last="Zou">Q M Zou</name><affiliation wicri:level="1"><nlm:affiliation>National Engineering Research Center of Immunological Products, Army Medical University, Chongqing 400038, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>National Engineering Research Center of Immunological Products, Army Medical University, Chongqing 400038</wicri:regionArea><wicri:noRegion>Chongqing 400038</wicri:noRegion></affiliation></author></analytic><series><title level="j">Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]</title><idno type="ISSN">0253-9624</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The outbreak of 2019 novel coronavirus (2019-nCoV) infection poses a serious threat to global public health. Vaccination is an effective way to prevent the epidemic of the virus. 2019-nCoV along with severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) belong to the same β-genus of coronavirus family. Base on the previous experience and the technical platform of developing SARS-CoV and MERS-CoV vaccines, scientists from all over the world are working hard and quickly on the related fields. There are substantial progress in these fields including the characterizing the 2019-nCoV virus, identification of candidate antigens and epitopes, establishment of animal models, characterizing the immune responses, and the design of vaccines. The development of 2019-nCoV vaccines cover all types: inactivated virus vaccine, recombinant protein vaccine, viral vector-based vaccine, mRNA vaccine, and DNA vaccine, et al. As of March 2020, two 2019-nCoV vaccines have entered phase I clinical trials. One is named as Ad5-nCoV developed by the Chinese Institute of Biotechnology of the Academy of Military Medical Sciences and Tianjin Cansino Biotechnology Inc. Ad5-nCoV is based on the replication-defective adenovirus type 5 as the vector to express 2019-nCoV spike protein. The another vaccine is mRNA-1273 developed by the National Institute of Allergy and Infectious Diseases and Moderna, Inc.. RNA-1273 is an mRNA vaccine expressing 2019-nCoV spike protein. Although the rapid development of 2019-nCoV vaccine, it still faces many challenges with unknown knowledge, including the antigenic characteristics of the 2019-nCoV, the influence of antigenic variation, the protective immune response of host, the protection of the elderly population, and the downstream manufacturing process of the new vaccine. The safety and efficacy of vaccines are the first priority for vaccine development and should be carefully evaluated.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32234130</PMID><DateRevised><Year>2020</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0253-9624</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>0</Issue><PubDate><Year>2020</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]</Title><ISOAbbreviation>Zhonghua Yu Fang Yi Xue Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)].</ArticleTitle><Pagination><MedlinePgn>E029</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.cn112150-20200317-00366</ELocationID><Abstract><AbstractText>The outbreak of 2019 novel coronavirus (2019-nCoV) infection poses a serious threat to global public health. Vaccination is an effective way to prevent the epidemic of the virus. 2019-nCoV along with severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) belong to the same β-genus of coronavirus family. Base on the previous experience and the technical platform of developing SARS-CoV and MERS-CoV vaccines, scientists from all over the world are working hard and quickly on the related fields. There are substantial progress in these fields including the characterizing the 2019-nCoV virus, identification of candidate antigens and epitopes, establishment of animal models, characterizing the immune responses, and the design of vaccines. The development of 2019-nCoV vaccines cover all types: inactivated virus vaccine, recombinant protein vaccine, viral vector-based vaccine, mRNA vaccine, and DNA vaccine, et al. As of March 2020, two 2019-nCoV vaccines have entered phase I clinical trials. One is named as Ad5-nCoV developed by the Chinese Institute of Biotechnology of the Academy of Military Medical Sciences and Tianjin Cansino Biotechnology Inc. Ad5-nCoV is based on the replication-defective adenovirus type 5 as the vector to express 2019-nCoV spike protein. The another vaccine is mRNA-1273 developed by the National Institute of Allergy and Infectious Diseases and Moderna, Inc.. RNA-1273 is an mRNA vaccine expressing 2019-nCoV spike protein. Although the rapid development of 2019-nCoV vaccine, it still faces many challenges with unknown knowledge, including the antigenic characteristics of the 2019-nCoV, the influence of antigenic variation, the protective immune response of host, the protection of the elderly population, and the downstream manufacturing process of the new vaccine. The safety and efficacy of vaccines are the first priority for vaccine development and should be carefully evaluated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Biopharmaceutical Research, West China Hospital, Sichuan University, Chengdu 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Biopharmaceutical Research, West China Hospital, Sichuan University, Chengdu 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Q M</ForeName><Initials>QM</Initials><AffiliationInfo><Affiliation>National Engineering Research Center of Immunological Products, Army Medical University, Chongqing 400038, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Yu Fang Yi Xue Za Zhi</MedlineTA><NlmUniqueID>7904962</NlmUniqueID><ISSNLinking>0253-9624</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="Publisher" Language="chi"><AbstractText>新型冠状病毒（2019-novel coronavirus，2019-nCoV）感染暴发流行对全球公众健康构成了严重威胁，疫苗接种是有效预防病毒感染流行的手段。2019-nCoV与急性呼吸综合征冠状病毒（SARS-CoV）和中东呼吸综合征冠状病毒（MERS-CoV）同属于β-冠状病毒。基于对SARS-CoV和MERS-CoV的了解，科学家对2019-nCoV病毒特征的研究、候选抗原及表位的鉴定、动物模型的建立、免疫应答的检测，疫苗的设计等工作取得了快速的进展。新型冠状病毒疫苗（新冠疫苗）的研发也取得了快速进展，新冠疫苗类型几乎涵盖了目前疫苗研究的所有形式，包括灭活疫苗、重组蛋白疫苗、病毒载体疫苗、核酸疫苗（mRNA疫苗与DNA疫苗）等。至2020年3月，已有2项新冠疫苗进入了I期临床试验，分别为我国军事医学科学院联合天津康希诺生物股份公司研发的基于腺病毒载体的重组新冠疫苗和美国Moderna公司的mRNA疫苗，两种疫苗均以2019-nCoV的刺突蛋白为抗原靶标。同时，新冠疫苗研发仍面临着许多未知的挑战，如2019-nCoV病毒抗原特征、抗原变异、机体的保护性免疫应答特征以及对老年及基础病人群是否具有保护，新型疫苗量产的生产工艺等方面仍需要更多的研究。疫苗研发具有其固有规律，在加快速度的同时，保证疫苗的安全性、有效性是必须的前提。.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">2019-nCoV</Keyword><Keyword MajorTopicYN="N">Animal models</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32234130</ArticleId><ArticleId IdType="doi">10.3760/cma.j.cn112150-20200317-00366</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Shi, Y" sort="Shi, Y" uniqKey="Shi Y" first="Y" last="Shi">Y. Shi</name></noRegion><name sortKey="Wang, N" sort="Wang, N" uniqKey="Wang N" first="N" last="Wang">N. Wang</name><name sortKey="Zou, Q M" sort="Zou, Q M" uniqKey="Zou Q" first="Q M" last="Zou">Q M Zou</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003671 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 003671 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:32234130
|texte= [Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:32234130" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |